Abstract:Ovarian cancer is the most lethal type of gynecological cancer. Due to its high heterogeneity and complicated pathological mechanisms, the 5-year survival rate of patients with ovarian cancer is <40%. Tumor cytoreductive surgery and systemic chemotherapy of platinum combined with paclitaxel are currently considered the gold standard for the treatment of ovarian cancer, and chemotherapy resistance has become a key constraint in improving the cure rate of ovarian cancer. Therefore, it is important to identify novel treatment methods and strategies for ovarian cancer. Targeted drugs can not only be used in combination with chemotherapy, but also act as maintenance therapy to promote patient survival time. PARP inhibitor is a novel type of ovarian cancer treatment targeted drug, which can induce an anticancer effect by inhibiting DNA damage and repair of ovarian cancer cells. The present study investigated the different effects of olaparib, cisplatin and paclitaxel in several dosages by single use and combinations on the proliferation of different human ovarian cancer cell lines, in order to verify the synergistic effects of the combinations of the three anticancer agents in pairs. The proliferation inhibitory rate of the cell lines was determined using a Cell Counting Kit-8 assay, while the combination index (CI) value of the combination of three agents in pairs was analyzed using Compusyn software. The proliferation was observed using a crystal violet assay, and the apoptosis ratio was measured via flow cytometry. The results of the present study revealed that the combination of cisplatin with olaparib group had a higher inhibition effect than each single group and had a higher dose-reduction index of >1 than the other two combinations at all concentrations in A2780 and OVCAR-3 cell lines. The difference in proliferation inhibition and induced apoptosis rate of A2780 cell lines was significant in the combination of cisplatin with olaparib group and the control group (P<0.01) at 0.25x IC50. For the OVCAR-3 cell line, the difference was also significant between two groups (P<0.05). The CI values in the A2780 cell line revealed significant differences between the low-dose group (0.0625x, 0.125x and 0.25x IC50) and the high-dose group (0.5x, 1.0x and 2.0x IC50) for the group that received the combination of cisplatin with olaparib (P<0.05). The present study highlighted that the group receiving a combination of cisplatin with olaparib exhibited the most significant synergistic effects among the three combinations, particularly at low doses.

Synergistic Effect of Black Tea Polyphenol, Theaflavin-3,3 '-Digallate with Cisplatin Against Cisplatin Resistant Human Ovarian Cancer Cells

Theaflavin-3,3′-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells

Inhibitory Effect of Black Tea Pigments, Theaflavin-3/3′-gallate Against Cisplatin-Resistant Ovarian Cancer Cells by Inducing Apoptosis and G1 Cell Cycle Arrest

Theaflavin-3, 3′-Digallate Induces Apoptosis and G2 Cell Cycle Arrest Through the Akt/MDM2/p53 Pathway in Cisplatin-Resistant Ovarian Cancer A2780/CP70 Cells

Myricetin Inhibits Proliferation of Cisplatin-Resistant Cancer Cells Through a P53-Dependent Apoptotic Pathway

Theaflavin-3,3-Digallate Suppresses Human Ovarian Carcinoma Ovcar-3 Cells By Regulating The Checkpoint Kinase 2 And P27 Kip1 Pathways

Theaflavin-3,3′-digallate Inhibits Ovarian Cancer Stem Cells Via Suppressing Wnt/β-Catenin Signaling Pathway

Combination Of Tetrandrine With Cisplatin Enhances Cytotoxicity Through Growth Suppression And Apoptosis In Ovarian Cancer In Vitro And In Vivo

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

Synergistic Effect of Tripterygium Glycosides and Cisplatin on Drug-Resistant Human Epithelial Ovarian Cancer Via ILK/GSK3β/Slug Signal Pathway.

Arsenic Trioxide And Cisplatin Synergism Increase Cytotoxicity In Human Ovarian Cancer Cells: Therapeutic Potential For Ovarian Cancer

Inhibitory Effects of the Four Main Theaflavin Derivatives Found in Black Tea on Ovarian Cancer Cells

Purified Tea (camellia Sinensis (L.) Kuntze) Flower Saponins Induce the P53-Dependent Intrinsic Apoptosis of Cisplatin-Resistant Ovarian Cancer Cells

Tea Polyphenols Modulate Antioxidant Redox System on Cisplatin‐induced Reactive Oxygen Species Generation in a Human Breast Cancer Cell

Proteomics Analysis Revealed Smad3 As a Potential Target of the Synergistic Antitumor Activity of Disulfiram and Cisplatin in Ovarian Cancer.

Synergetic Effect of Poly (Adp-Ribosyl) Polymerase (PARP) Inhibitor and Cisplatin on Ovarian Cancer

Combination Treatment with Cisplatin, Paclitaxel and Olaparib Has Synergistic and Dose Reduction Potential in Ovarian Cancer Cells

Oxyresveratrol Enhances the Anti-Cancer Effect of Cisplatin against Epithelial Ovarian Cancer Cells through Suppressing the Activation of Protein Kinase B (AKT)

EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer

Synergism from Combination of Cisplatin and A Trans-Platinum Compound in Ovarian Cancer Cell Lines

Combination of FTY720 with Cisplatin Exhibits Antagonistic Effects in Ovarian Cancer Cells: Role of Autophagy